本网站内容仅面向医疗专业人士

  

什么是Motiva 魔滴 ？

Motiva 魔滴假体是第6代的隆胸假体，现已在马来西亚上市。经过多年的科学研究和测试，Motiva 魔滴 推出了创新的功能，解决了前几代假体所面临的问题。这使得生产的乳房假体能够带来自然美观的隆胸效果和最高的安全度。

Motiva 魔滴的独特产品之一是Ergonomix® 假体。Ergonomix® 不仅使乳房看起来无比自然，而且感觉也及其仿真。它能够随着乳房移动，在躺下时呈现圆盘状，在站起来时呈现自然垂坠的水滴状。此外，接受Motiva 魔滴培训的外科医生可以实现最小2.5厘米的疤痕。

Motiva 魔滴假体的并发症发生率也较低，包括罕见的包膜挛缩、假体破裂、血清肿和乳房假体相关的间变性大细胞淋巴瘤(BIA-ALCL)。Motiva 魔滴 还在全球实施了超过160万例的隆胸手术[1]。现在，Motiva 魔滴 已在马来西亚售卖！

[1] Establishment Labs. Post-Market Surveillance Report. Q4, 2020

SmoothSilk®/ SilkSurface® 纳米丝绸外层膜

Motiva魔滴假体的外壳是由被称为SmoothSilk®/SilkSurface®的光滑纳米纹理表面构成。通过3D纳米技术印刷而成，能够实现最佳的生物相容性，最大限度地减少组织的反应性和假体周围生物膜的生长。

这使得植入过程更加容易，同时将双囊、晚期血清肿和乳房假体相关的间变性大细胞淋巴瘤(BIA-ALCL) 等并发症的风险降至最低。

表面形貌

Image

< 1%包膜挛缩率

包膜挛缩历来与传统的光滑假体有关联。然而，大孔洞粗糙面(Macrotextured)被观察到与慢性炎症相关的几种并发症有关联。这可能导致假体移位[2]、晚期并发症，甚至恶性肿瘤[3]。

SmoothSilk® 表面促进最佳反应 [4,5]，其能够通过调节参与炎症和纤维化反应 [4,5,7] 的细胞的活性，从而降低慢性炎症并发症的风险[6]。

  1. Sforza M, Zaccheddu R, Alleruzzo A, et al. Preliminary 3-Year Evaluation of Experience with SilkSurface and VelvetSurface Motiva Silicone Breast Implants: A Single-Center Experience with 5813 Consecutive Breast Augmentation Cases. Aesthetic Surg J. 2018;38:S62-S73. doi:10.1093/asj/sjx150
  2. Marcelli S, Aso J. Preliminary outcomes and comparison of polytech POLYtxt and MESMOsensitive breast implants with focus on late seroma: Single-surgeon, retrospective cohort study on 621 consecutive aesthetic breast surgery cases. J Plast Reconstr Aesthet Surg. 2021 Jan 11:S1748-6815(21)00026-7. doi: 10.1016/j.bjps.2020.12.092.
  3. SCHEER Final Opinion on the safety of breast implants in relation to anaplastic large cell lymphoma. 2021 (March):1-43. Available at: https://ec.europa.eu/health/sites/health/files/scientific_committees/scheer/docs/scheer_o_018.pdf
  4. Cappellano G, Ploner C, Lobenwein S, et al. Immunophenotypic characterization of human T cells after in vitro exposure to different silicone breast implant surfaces. PLoS One. 2018;13(2):1-14. doi:10.1371/journal.pone.0192108
  5. Nam S, Lee M, Shin BH, Elfeky B, Lee YU, Moon DH. Characterization of BellaGel SmoothFine ® Implant Surfaces and Correlation with Capsular Contracture. 2019:196-211. doi:10.4236/jbnb.2019.104012
  6. Quirós MC, Bolaños MC, Fassero JJ. Six-year prospective outcomes of primary breast augmentation with nano surface implants. Aesthetic Surg J. 2019;39(5):495-508. doi:10.1093/asj/sjy196
  7. Pontes GH, Vargas Guerrero LA, Mendes Carneiro Filho FS, et al. Reduced Remodeling Biomarkers TissueExpression in Nanotextured Compared with Polyurethane Implants Capsules: A Study in Rats. Aesthetic Surg J. November 2020. doi:10.1093/asj/sjaa315